Nature and Science of Sleep
As of May 2024, about 22% of adults who had been told by a doctor that they are overweight or obese said they had ever taken a GLP-1 drug, according to a KFF poll
GHRH peptides like CJC-1295 have been associated with improved slow-wave sleep architecture in research models, potentially supporting recovery processes that depend on nocturnal GH pulses
Studies show that 5-amino-1-methylquinolinium injection inhibits NNMT, normalizes nicotinamide metabolism, elevates NAD+, reduces oxidative stress in cells, suppresses apoptosis, preserves cell function, and promotes insulin secretion, supporting longterm glycemic control
This process, known as glutathione conjugation, is catalysed by enzymes called glutathione S-transferases (GSTs)
Both Eli Lilly and Novo Nordisk are competing to bring an oral pill version of a GLP-1 drug to market, as a daily pill could be more accessible and may be more appealing for people who do not want to use weekly GLP-1 injectable medications
